Biomarkers and classifier of psoriasis and methods of treatment
AssigneeIcahn School of Medicine at Mount Sinai
InventorsAna Brandusa Pavel, Emma Guttman-Yassky
Life of this patent
Estimating the term…
Abstract
The present invention features biomarkers for diagnosis and treatment of dermatological diseases, e.g., psoriasis and atopic dermatitis. The disclosure provides a minimally invasive method of determining levels of biomarkers (e.g., NOS2/iNOS) in surface skin samples.
Claims24
A method of treating psoriasis, comprising discriminating between atopic dermatitis and psoriasis in a human subject exhibiting an indeterminate lesion, further comprising:
- (a) obtaining a surface skin sample from the subject exhibiting a skin lesion by tape-strip applied to a selected skin surface, wherein application of the tape-strip to the selected skin surface transfers the surface skin sample to the tape-strip;
- (b) determining the level of NOS2/iNOS biomarker in the surface skin sample;
- (c) comparing the level of the NOS2/iNOS biomarker in the surface skin sample to a reference level of NOS2/iNOS biomarker in a control sample;
- (d) determining that the subject has psoriasis if the levels of NOS2/iNOS biomarker is higher than the reference level of NOS2/iNOS biomarkers in the control sample;
- (e) determining that the subject has atopic dermatitis if the NOS2/iNOS level in the surface skin sample are similar to or lower than the reference levels in the control sample;
- and
- (f) administering a therapeutically effective amount of a psoriasis therapy to the human subject identified as having psoriasis.
A method of treating atopic dermatitis, comprising discriminating between atopic dermatitis and psoriasis in a human subject exhibiting an indeterminate lesion, further comprising:
- (a) obtaining a surface skin sample from the subject exhibiting a skin lesion by tape-strip applied to a selected skin surface, wherein application of the tape-strip to the selected skin surface transfers the surface skin sample to the tape-strip;
- (b) determining the level of NOS2/iNOS biomarker in the surface skin sample;
- (c) comparing the level of the NOS2/iNOS biomarker in the surface skin sample to a reference level of NOS2/iNOS biomarker in a control sample;
- (d) determining that the subject has psoriasis if the levels of NOS2/iNOS biomarker is higher than the reference level of NOS2/iNOS biomarkers in the control sample;
- (e) determining that the subject has atopic dermatitis if the NOS2/iNOS level in the surface skin sample are similar to or lower than the reference levels in the control sample;
- and
- (f) administering a therapeutically effective amount of an atopic dermatitis therapy to the human subject identified as having atopic dermatitis.
Dependencies are inferred from the claim text.